10x Genomics

$146.13
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$25.81 (-14.90%) Today

-$1.27 (-0.86%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell 10x Genomics and other stocks, options, and ETFs commission-free!

About TXG

10x Genomics, Inc. Class A Common Stock, also called 10x Genomics, is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell transcriptomics, single cell genomics, single cell epigenomes, linked-reads genomics and spatial transcriptomics. The company’s products include Single Cell Gene Expression, Immune Profiling, CNV, ATAC, and Genome and Exome. 10X Genomics was founded by Serge Saxonov, Ben Hindson and Kevin D. Ness on July 2, 2012 and is headquartered in Pleasanton, CA. The listed name for TXG is 10x Genomics, Inc. Class A Common Stock.

CEO

Serge Saxonov

Employees

584

Headquarters

Pleasanton, California

Founded

2012

Market Cap

15.12B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

814.09K

High Today

$173.67

Low Today

$146.50

Open Price

$171.55

Volume

1.42M

52 Week High

$201.70

52 Week Low

$48.78

Analyst Ratings

88%

of 8 ratings

Buy

88%

Hold

13%

Sell

TXG Earnings

-$0.65

-$0.43

-$0.22

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected May 10, After Hours